ACE2 and COVID-19: Since our findings indicate that an ACE2-Fc without Fc effector functionality can attenuate disease severity and improve lung pathology in hamsters, in agreement with a published study (26), ACE2-Fc decoys with silenced Fc effector functionality might be effective and safer for the treatment of severe COVID-19, allowing their use in hospitalized patients in whom monoclonal antibody use is contraindicated because of the potential for harm.